Call for proposals

23rd Call for proposals 2020 - Innovative Medicines Initiative 2 Joint Undertaking - H2020-JTI-IMI2 H2020-JTI-IMI2-2020-23-two-stage Open!

The Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) has been created following the principles below:

Research related to the future of medicine should be undertaken in areas where societal, public health and biomedical industry competitiveness goals are aligned and require the pooling of resources and greater collaboration between the public and private sectors, with the involvement of Small- and Medium- sized Enterprises (SMEs).
The scope of the initiative should be expanded to all areas of life science research and innovation.
The areas should be of public health interest, as identified by the World Health Organisation (WHO) report on priority medicines for Europe and the World

This call covers the following topics:

IMI2-2020-23-01: Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework
IMI2-2020-23-02: Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
IMI2-2020-23-03: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
IMI2-2020-23-04: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence
IMI2-2020-23-05: Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies
IMI2-2020-23-06: Behavioural Model of Factors Affecting Patient Adherence

The Community provisional funding available for the call for proposals is:

29 September 2020 - 21 days ago (Deadline for the presentation of proposals)
17 March 2021 - in 4 months (Deadline for the presentation of proposals)

Opened to the following bodies or institutes with legal status established in the covered areas:

Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:

Directorate-General for Research